• Publications
  • Influence
Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.
TLDR
AAV patients with renal involvement who needed RRT had the worst survival probability and the only major determinants for long-term renal survival were renal function at 6 months and renal relapses. Expand
Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data
TLDR
Post hoc analysis of combined trial data suggest that stopping AZA maintenance therapy does not lead to a significant increase in relapse rate andAZA maintenance for more than 18 months after diagnosis does not significantly influence relapse-free survival. Expand
Pregnancy in women diagnosed with Antineutrophil cytoplasmic antibody–associated vasculitis: Outcome for the mother and the child
TLDR
Antineutrophil cytoplasmic antibody–associated vasculitis (AAV) is infrequently seen in women of childbearing age and is associated with complications. Expand
Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?
TLDR
This review discusses the different aspects of maintenance therapy in AAV based on reported cohorts and studies, including the different agents, therapy duration, efficacy or lack thereof and future directions. Expand
Performance of two strategies for urgent ANCA and anti-GBM analysis in vasculitis.
TLDR
The Dotblot and Phadia ELiA on anti-GBM, anti-PR3 (s) and anti-MPO(s) performed excellently; results were almost identical to routine ELISA. Expand
Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil
TLDR
This randomized trial suggests that extended azathioprine maintenance therapy has only a limited effect on the prevention of relapse in patients with PR3-AAV at 4 years after diagnosis. Expand
Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
TLDR
Although antiviral agents are available, vaccination should be recommended for preventing HZ in transplant patients considering their complicated condition and weak organ function and extra efforts are needed to increase vaccine usage according to guidelines. Expand
The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody–associated Glomerulonephritis
TLDR
In this study in 110 Dutch patients, the recurrence rate of AAGN within 5 years after kidney transplantation appeared slightly higher than in previous reports, emphasizing the importance of clinical vigilance, because early treatment might be critical to rescuing the allograft. Expand
Increased incidence of herpes zoster in patients on renal replacement therapy cannot be explained by intrinsic defects of cellular or humoral immunity to varicella‐zoster virus
TLDR
Increased incidence of herpes zoster in patients receiving RRT cannot be explained by intrinsic defects of cellular or humoral immunity to VZV as measured by the methods used in this study, although older age and previous transplantation were associated with decreased cellular immunity toVZV. Expand
Torquetenovirus Serum Load and Long-Term Outcomes in Renal Transplant Recipients
TLDR
TTV levels decrease in the years following renal transplantation, but remain elevated longer than previously thought, showing that TTV level may aid in predicting long-term outcomes, all-cause mortality and death due to an infectious cause in renal transplant patients sampled over one year post-transplantation. Expand
...
1
2
...